NCT06677814

Brief Summary

Background: Premature ejaculation (PE) is a common sexual dysfunction that can significantly impact the quality of life and psychological well-being of affected individuals. Anxiety disorders, often comorbid with PE, exacerbate symptoms and complicate treatment outcomes. There is a critical need for a reliable prediction model to identify patients at risk of developing anxiety disorders associated with PE. Objective: The primary aim of this study is to develop and validate a predictive model that accurately identifies premature ejaculation patients who are at high risk of developing anxiety disorders. The model will be designed to facilitate early intervention strategies and improve patient outcomes. Methods: This prospective observational study will enroll male patients diagnosed with PE from multiple clinical centers. Participants will undergo comprehensive assessments including validated questionnaires, clinical interviews, and medical history reviews to collect baseline data on potential predictors of anxiety disorders. Machine learning algorithms will be utilized to analyze the collected data and derive a predictive model. External validation will be conducted using a separate cohort of patients not involved in the initial model development phase. Outcome Measures: The primary outcome measure will be the accuracy of the predictive model in identifying patients who subsequently develop anxiety disorders within a predefined follow-up period. Secondary outcomes include evaluating the model's sensitivity, specificity, positive predictive value, and negative predictive value. Significance: Successful development and validation of this prediction model could lead to improved patient care through targeted interventions and personalized treatment plans for those at risk of anxiety disorders related to PE. This research may also contribute to a better understanding of the complex interplay between sexual dysfunction and mental health.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
700

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2024

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 25, 2024

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

October 31, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 7, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 25, 2025

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

November 7, 2024

Status Verified

October 1, 2024

Enrollment Period

1 year

First QC Date

October 31, 2024

Last Update Submit

November 5, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Anxiety State of patients

    Use the Mini International Neuropsychiatric Interview (MINI) to conduct a structured interview with the patient to determine if they have an anxiety disorder.

    Within three months after the patient is diagnosed with premature ejaculation.

  • Accuracy of the Prediction Model

    Evaluate the accuracy of the prediction model by comparing its predictions against actual diagnoses of anxiety disorders.

    Through study completion, an average fo 1 year

Secondary Outcomes (2)

  • Sensitivity of the Prediction Model

    Through study completion, an average fo 1 year

  • Specificity of the Prediction Model

    Through study completion, an average fo 1 year

Study Arms (2)

Training cohort

This cohort data will be used to screen for independent risk factors for anxiety disorders in patients with premature ejaculation and to initially construct a risk prediction model.

Validation cohort

This cohort data will be used to verify the performance and stability of the risk prediction model to ensure the promotion and use of the model.

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Participants for this study will be male patients diagnosed with premature ejaculation (PE). Sample Size: Approximately 700 patients are expected to be recruited for this study. The sample size was determined based on previous studies and statistical calculations to ensure adequate statistical power. Recruitment Sites: Participants will be recruited from four tertiary hospitals within the country.

You may qualify if:

  • Comply with the international medical premature ejaculation diagnostic criteria
  • Individuals with a "heterosexual" orientation who engage in vaginal intercourse
  • Having a stable relationship with "monogamy"
  • The International Index of Erectile Function-5 scale is ≥17 points, indicating that the patient has no erectile dysfunction or only mild erectile dysfunction
  • Be informed of the purpose of this study, support this study, and complete the informed consent form

You may not qualify if:

  • Minors under the age of 18
  • Individuals with a sexual orientation of "gay" or "bisexual"
  • The judgment of "ejaculation too fast" is based only on masturbation or non-vaginal sexual intercourse
  • The score of the premature ejaculation self-assessment scale is ≤8 points
  • Suffering from diseases that may affect anxiety symptoms (hyperthyroidism/hypothyroidism, digestive diseases, malignant tumors, etc.)
  • Within 2 months, have taken anti-anxiety drugs and/or drugs for PE treatment
  • Those with a history of severe neurological diseases (such as epilepsy) and/or a history of schizophrenia, bipolar disorder, or other mental disorders
  • Poor cooperation during diagnostic interviews

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Xi'an Daxing Hospital affiliated to Yan'an University

Xi'an, Shaanxi, 710016, China

RECRUITING

Xijing Hospital

Xi'an, Shaanxi, 710032, China

RECRUITING

MeSH Terms

Conditions

Premature EjaculationAnxiety Disorders

Condition Hierarchy (Ancestors)

Ejaculatory DysfunctionGenital Diseases, MaleGenital DiseasesUrogenital DiseasesSexual Dysfunction, PhysiologicalMale Urogenital DiseasesSexual Dysfunctions, PsychologicalMental Disorders

Central Study Contacts

Jianlin Yuan, Doctor

CONTACT

Zhaoqing Li, bachelor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 31, 2024

First Posted

November 7, 2024

Study Start

March 25, 2024

Primary Completion

March 25, 2025

Study Completion

May 1, 2026

Last Updated

November 7, 2024

Record last verified: 2024-10

Locations